切换至 "中华医学电子期刊资源库"

中华眼科医学杂志(电子版) ›› 2025, Vol. 15 ›› Issue (01) : 13 -20. doi: 10.3877/cma.j.issn.2095-2007.2025.01.003

论著

神经退行性疾病患者泪膜稳定性和角膜敏感性改变的临床研究
王凡1, 何钰嵩2, 吉玲1, 于晴1, 牟宁1, 王雨蒙1, 孙妍2, 陈荔2, 李明新1, 王贺1,   
  1. 1. 221000 徐州医科大学附属医院眼科
    2. 221000 徐州医科大学附属医院2024级硕士研究生
  • 收稿日期:2024-12-15 出版日期:2025-02-28
  • 通信作者: 王贺
  • 基金资助:
    江苏省中医药科技发展计划项目(QN202330)

Changes in tear film stability and corneal sensitivity in patients w ith neurodegenerative diseases

Fan Wang1, Yusong He2, ling Ji1, Qing Yu1, Ning Mu1, Yumeng Wang1, Yan Sun2, Li Chen2, Mingxin Li1, He Wang1,   

  1. 1. Department of Ophthalmology,the Affiliated Hospital of Xuzhou Medical University,Xuzhou 221000,China
    2. Master′s degree2024,the Affiliated Hospital of Xuzhou Medical University,Xuzhou 221000,China
  • Received:2024-12-15 Published:2025-02-28
  • Corresponding author: He Wang
引用本文:

王凡, 何钰嵩, 吉玲, 于晴, 牟宁, 王雨蒙, 孙妍, 陈荔, 李明新, 王贺. 神经退行性疾病患者泪膜稳定性和角膜敏感性改变的临床研究[J/OL]. 中华眼科医学杂志(电子版), 2025, 15(01): 13-20.

Fan Wang, Yusong He, ling Ji, Qing Yu, Ning Mu, Yumeng Wang, Yan Sun, Li Chen, Mingxin Li, He Wang. Changes in tear film stability and corneal sensitivity in patients w ith neurodegenerative diseases[J/OL]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2025, 15(01): 13-20.

目的

探讨神经退行性疾病(ND)患者的角膜敏感性和泪膜稳定性。

方法

选取2023年1月至12月于徐州医科大学附属医院神经内科招募诊断为ND患者145例(145只眼),同期招募非ND患者182例(182只眼)。其中,男性150例(150只眼),女性177例(177只眼);年龄30~82岁,平均年龄(51.7±7.8)岁。按疾病类型,ND患者分为包括阿尔茨海默病(AD)、弗里德赖希共济失调(FA)、帕金森病(PD)、多发性硬化(MS)及亨廷顿舞蹈症(HD)组;对照组按ND组患者年龄和性别配对。使用Cochet-Bonnet触觉计测量角膜敏感性,LipiView眼表面干涉仪检测瞬目频率。泪液检测包括眼表疾病指数量表(OSDI)评分评分、泪河高度(TMH)、非接触式泪膜破裂时间(NIBUT)、角膜荧光素染色评分及泪膜脂质层厚度(LLT)。OSDI、TMH、NIBUT、角膜荧光素染色评分、LLT、瞬目频率及角膜敏感性符合正态分布,以±s描述,比较采用独立样本t检验;性别为二分类变量,以例数和百分比表示,采用卡方检验。

结果

ND患者145例(145只眼)中,AD、MS、PD、FA及HD者分别有36例(36只眼)、30例(30只眼)、50例(50只眼)、13例(13只眼)及16例(16只眼),分别占24.83%、20.69%、34.48%、8.97%及11.03%。非ND患者182例(182只眼)中,AD、MS、PD、FA及HD对照组分别有43例(43只眼)、33例(33只眼)、50例(50只眼)、28例(28只眼)及28例(28只眼),分别占23.63%、18.13%、27.47%、15.39%及15.39%。AD、FA、PD、MS及HD组患者OSDI评分、TMH、NIBUT、角膜荧光素染色评分、LLT、瞬目频率及角膜敏感性分别为(27.97±8.12)分、(27.30±6.89)分、(24.94±5.79)分、(26.31±6.78)分、(25.38±5.71)分、(0.16±0.02)mm、(0.22±0.02)mm、(0.17±0.01)mm、(0.23±0.02)mm、(0.17±0.02)mm、(5.25±1.27)s、(5.33±1.21)s、(5.84±1.42)s、(6.23±1.48)s、(6.19±1.42)s、(2.03±0.14)分、(1.77±0.77)分、(1.26±0.63)分、(1.31±0.48)分、(1.31±0.48)分、(68.50±11.57)μm、(70.60±10.96)μm、(69.90±9.25)μm、(71.31±6.13)μm、(71.38±7.72)μm、(8.72±1.11)次/min、(8.77±1.01)次/min、(8.88±1.54)次/min、(8.31±0.86)次/min及(8.25±0.86)次/min、(37.36±9.89)mm、(39.00±12.25)mm、(38.40±9.87)mm、(39.23±9.97)mm及(36.88±9.64)mm;其对应对照组分别为(14.05±5.28)分、(12.03±4.65)分、(17.58±5.20)分、(14.11±5.42)分、(14.50±4.81)分、(0.22±0.03)mm、(0.25±0.03)mm、(0.23±0.02)mm、(0.25±0.02)mm、(0.24±0.02)mm、(12.35±2.84)s、(12.12±1.90)s、(13.16±2.07)s、(12.43±2.03)s、(12.32±1.83)s、(0.42±0.50)分、(0.33±0.48)分、(0.22±0.42)分、(0.25±0.44)分、(0.21±0.42)分、(70.42±9.69)μm、(69.30±9.22)μm、(70.34±10.28)μm、(70.14±8.70)μm、(70.75±8.78)μm、(12.63±1.27)次/min、(12.91±1.38)次/min、(12.30±1.42)次/min、(12.82±1.44)次/min、(12.93±1.48)次/min、(55.35±5.61)mm、(55.61±5.27)mm、(56.50±4.55)mm、(54.82±6.16)mm及(55.71±5.72)mm。AD、FA及PD组与对照组OSDI评分、TMH、NIBUT、角膜荧光素染色评分、瞬目频率及角膜敏感性比较的差异有统计学意义(t=-6.500,-6.440,-5.673,10.412,-4.614,-13.883,-14.706,-16.710,-20.597,-7.126,-6.053,-7.208,-7.450,-6.723,-8.198,-10.144,-7.615,-11.780;P<0.05)。与对照组相比,FA组和HD组患者TMH降低、FA组和HD组患者NIBUT缩短、FA组和HD组患者角膜荧光素染色评分升高、FA组和HD组患者瞬目频率降低以及FA组和HD组患者角膜敏感性降低。

结论

不同类型的ND患者普遍存在泪膜稳定性和角膜敏感性降低。

Objective

The aim of this study is to investigate corneal sensitivity and tear film stability in patients with neurodegenerative diseases(ND).

Methods

A total of 145 clinically diagnosed ND patients(145 eyes)and 182 age-and gender-matched non-ND controls(182 eyes)from the Department of Neurology,Affiliated Hospital of Xuzhou Medical University between January and December 2023.The cohort comprised 150 males and 177 females with an average age of(51.7±7.8)year-old(ranging from 30 to 82 year-old).According to the disease type,patients were divided into Alzheimer′s disease(AD),multiple sclerosis(MS),Parkinson′s disease(PD),Friedreich′s ataxia(FA),Huntington′s disease(HD),and control groups were established with matched demographics.Ocular assessments included corneal sensitivity measurement using Cochet-Bonnet esthesiometer.Blink frequency analysis via LipiView ocular surface interferometer tear film evaluation through ocular surface disease index(OSDI),tearmeniscus height(TMH),non-invasive tear film breakup time(NIBUT),corneal fluorescein staining(CFS),lipid layer thickness(LLT).OSDI,TMH,NIBUT,corneal fluorescein staining score,LLT,blink frequency and corneal sensitivity were all in line with normal distribution,and were described by(±s),and the comparison between groups was performed with t test.Gender was a dichotomous variable,expressed in cases and percentages,using chi-square test.

Results

ND subgroups included AD patients with 36 cases(36 eyes),MS patientswith 30 cases(30 eyes),PD patients with 50 cases(50 eyes),FA patients with(13 cases)13 eyes and HD patients with 16 cases(16 eyes);AD patients control with 43 cases(43 eyes),MSpatients controlwith 33 cases(33 eyes),PD patients controlwith 50 cases(50 eyes),FA patients controlwith 28 cases(28 eyes),and HD patients control with 28 cases(28 eyes).OSDI scores TMH,NIBUT,corneal fluorescein staining score,LLT,the blink frequency and corneal sensitivity of patients in AD,FA,PD,MSand HD groupswere(27.97±8.12)score,(27.30±6.89)score,(24.94±5.79)score,(26.31±6.78)score,(25.38±5.71)score,respectively(0.16±0.02)mm,(0.22±0.02)mm,(0.17±0.01)mm,(0.23±0.02)mm,(0.17±0.02)mm,(5.25±1.27)s,(5.33±1.21)s,(5.84±1.42)s,(6.23±1.48)s,(6.19±1.42)s,(2.03±0.14)points,(1.77±0.77)points,(1.26±0.63)points,(1.31±0.48)points,(1.31±0.48)points,(68.50±11.57)μm,(70.60±10.96)μm,(69.90±9.25)μm,(71.31±6.13)μm,(71.38±7.72)μm,(8.72±1.11)times/min,(8.77±1.01)times/min,(8.88±1.54)times/min,(8.31±0.86)times/min and(8.25±0.86)times/min,(37.36±9.89)mm,(39.00±12.25)mm,(38.40±9.87)mm,(39.(23±9.97)mm and(36.88±9.64)mm.The corresponding control groups were(14.05±5.28)score,(12.03±4.65)score,(17.58±5.20)score,(14.11±5.42)score,(14.50±4.81)score,respectively(0.22±0.03)mm,(0.25±0.03)mm,(0.23±0.02)mm,(0.25±0.02)mm,(0.24±0.02)mm,(12.35±2.84)s,(12.12±1.90)s,(13.16±2.07)s,(12.43±2.03)s,(12.32±1.83)s,(0.42±0.50)points,(0.33±0.48)points,(0.22±0.42)points,(0.25±0.44)points,(0.21±0.42)points,70.42±9.69)μm,(69.30±9.22)μm,(70.34±10.28)μm,(70.14±8.70)μm,(70.75±8.78)μm,(12.63±1.27)times/min,(12.91±1.38)times/min,(12.30±1.42)times/min,(12.82±1.44)times/min,(12.93±1.48)times/min,(55.35±5.61)mm,(55.61±5.27)mm,(56.50±4.55)mm,(54.82±4.55)mm,6.16)mm and(55.71±5.72)mm.The differences between AD,FA and PD groups and the corresponding control group were statistically significant(t=-6.500,-6.440,-5.673,10.412,-4.614,-13.883,-14.706,-16.710,-20.597,-7.126, -6.053, -7.208, -7.450, -6.723, -8.198, -10.144, -7.615,-11.780;P<0.05).Compared with the control group,the TMH of patients in FA group and HD group decreased.Compared with the control group,the nibut time of patients in FA group and HD group was shortened.Compared with the control group,the corneal fluorescein staining scores of patients in FA group and HD group were increased.Compared with the control group,the blink frequency of patients in FA group and HD group was decreased.Compared with the control group,the corneal sensitivity of patients in FA group and HD group was decreased.

Conclusions

Patients with various NDs exhibit characteristic dry eye manifestations characterized by impaired tear film stability and diminished corneal sensitivity.

表1 AD、MS及PD组患者泪膜稳定性和角膜敏感性的比较(¯x±s
组别 眼数(只眼) OSDI(分) NIBUT(s) 角膜荧光素染色评分(分) TMH(mm) LLT(μm) 瞬目频率(次/min) 角膜敏感性(mm)
AD组 36 27.97±8.12 5.25±1.27 2.03±0.14 0.16±0.02 68.50±11.57 8.72±1.11 37.36±9.89
对照组 43 14.05±5.28 12.35±2.84 0.42±0.50 0.22±0.03 70.42± 9.69 12.63±1.27 55.35±5.61
-6.500 -13.883 -7.126 -10.412 -0.803 -7.45 -10.144
<0.05 <0.05 <0.05 <0.05 >0.05 <0.05 <0.05
组别 眼数(只眼) OSDI(分) NIBUT(s) 角膜荧光素染色评分(分) TMH(mm) LLT(μm) 瞬目频率(次/min) 角膜敏感性(mm)
MS组 30 27.30±6.89 5.33±1.21 1.77±0.77 0.22±0.02 70.60±10.96 8.77±1.01 39.00±12.25
对照组 33 12.03±4.65 12.12±1.90 0.33±0.48 0.25±0.03 69.30±9.22 12.91±1.38 55.61± 5.27
-6.440 -16.710 -6.053 -4.614 0.510 -6.723 -7.615
<0.05 <0.05 <0.05 <0.05 >0.05 <0.05 <0.05
组别 眼数(只眼) OSDI(分) NIBUT(s) 角膜荧光素染色评分(分) TMH(mm) LLT(μm) 瞬目频率(次/min) 角膜敏感性(mm)
PD组 50 24.94±5.79 5.84±1.42 1.26±0.63 0.17±0.01 69.90± 9.25 8.88±1.54 38.40±9.87
对照组 50 17.58±5.20 13.16±2.07 0.22±0.42 0.23±0.02 70.34±10.28 12.30±1.42 56.50±4.55
-5.673 -20.597 -7.208 -14.706 -0.225 -8.198 -11.780
<0.05 <0.05 <0.05 <0.05 >0.05 <0.05 <0.05
图1 神经退行性疾病患者泪河高度外观照相 图1A~1F分别示裂隙灯显微镜下阿尔茨海默病、弗里德赖希共济失调、帕金森病、多发性硬化及亨廷顿舞蹈症患者的泪河高度照相(×16) 图2 神经退行性疾病患者非接触式泪膜破裂时间的比较 图2A~2F分别示阿尔茨海默病、弗里德赖希共济失调、帕金森病、多发性硬化及亨廷顿舞蹈症患者的非接触式泪膜破裂时间
图3 神经退行性疾病患者角膜荧光素染色彩色照相 图3A~3F分别示裂隙灯显微镜下阿尔茨海默病、弗里德赖希共济失调、帕金森病、多发性硬化及亨廷顿舞蹈症患者的角膜荧光素染色彩色照相(×16)
[1]
Marcos-Rabal P,González-Fuentes J,Castro-Vázquez L,et al.Neurodegenerative diseases:a multidisciplinary approach[J].Curr Pharm Des,2021,27(30):3305-3336.
[2]
Marchesi N, Fahmideh F, Boschi F, et al. Ocular neurodegenerative diseases:interconnection between retina and cortical areas[J].Cells,2021,10(9):2394.
[3]
Mancino R,Cesareo M,Martucci A,et al.Neurodegenerative process linking the eye and the brain[J].Curr Med Chem,2019,26(20):3754-3763.
[4]
Musicco M,Padovani A,Sorbi S,et al:Position paper of the Italian Society for the study of Dementias(SINDEM)on the proposal of a new lexicon on Alzheimer disease[J].Neurol Sci,2012,33(1):201-208.
[5]
Martinez-Martin P,Falup-Pecurariu C,Rodriguez-Blazquez C,et al.Dementia associated with parkinsons disease:applying the movement disorder society task force criteria[J].Parkinsonism Relat Disord,2011,17(8):621-624.
[6]
Marelli C,Figoni J,Charles P,et al.Annual change in friedreichs ataxia evaluated by the scale for the assessment and rating of ataxia(SARA)is independent of disease severity[J].Mov Disord,2011,27(1):135-138.
[7]
Claassen DO,Philbin M,Carroll B.Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington′s disease:a review of clinical trial data[J].Expert Opin Pharmacother,2019,20(18):2209-2221.
[8]
Matsui H,Kumano Y,Zushi I,et al.Corneal sensation after correction ofmyopia by photorefractive keratectomy and laser in situ keratomileusis[J].JCataract Refract Surg,2001,27(3):370-373.
[9]
Kumano Y,Matsui H,Zushi I,et al.Recovery of corneal sensation after myopic correction by laser in situ keratomileusis with a nasal or superior hinge[J].JCataractRefractSurg,2003,29(4):757-761.
[10]
Pelak VS, Hall DA. Neuro-ophthalmic manifestations of neurodegenerative disease[J].Ophthalmol Clin North Am,2004,17(3):311-320.
[11]
Romaus-Sanjurjo D, Regueiro U, López-López M, et al.Alzheimer′s disease seen through the eye:ocular alterations and neurodegeneration[J].Int JMol Sci,2022,23(5):2486.
[12]
Ungureanu L,Chaudhuri KR,Diaconu S,et al.Dry eye in Parkinson′s disease:a narrative review[J].Front Neurol,2023,14:1236366.
[13]
Nagino K, Sung J, Oyama G, et al. Prevalence and characteristics of dry eye disease in Parkinson′s disease:a systematic review andmeta-analysis[J].SciRep,2022,12(1):18348.
[14]
Kraker JA,Xu SC,Flanagan EP,etal.Ocularmanifestations of multiple sclerosis: a population-based study [J]. J Neuroophthalmol,2024,44(2):157-161.
[15]
Uttara B,Singh AV,Zamboni P,et al.Oxidative stress and neurodegenerative diseases:a review of upstream and downstream antioxidant therapeutic options[J].Curr Neuropharmacol,2009,7(1):65-74.
[16]
Teleanu DM,Niculescu AG,Lungu II,et al.An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases[J].Int JMol Sci,2022,23(11):5938.
[17]
Vejux A.Cell Death,Inflammation and oxidative stress in neurodegenerative diseases: mechanisms and cytoprotective molecules[J].Int JMol Sci,2021,22(24):13657.
[18]
Vereertbrugghen A,Galletti JG.Corneal nerves and their role in dry eye pathophysiology[J].Exp Eye Res,2022,222:109191.
[19]
Pflugfelder SC,Stern ME.Biological functions of tear film[J].Exp Eye Res,2020,197:108115.
[20]
Huang R, Su C, Fang L, et al. Dry eye syndrome:comprehensive etiologies and recent clinical trials[J].Int Ophthalmol,2022,42(10):3253-3272.
[21]
Periman LM,Perez VL,Saban DR,et al.The immunological basis of dry eye disease and current topical treatmentoptions[J].JOcul Pharmacol Ther,2020,36(3):137-146.
[22]
Woodruff-Pak DS,Papka M, Romano S, et al. Eyeblink classical conditioning in Alzheimer′s disease and cerebrovascular dementia[J].Neurobiol Aging,1996,17(4):505-512.
[23]
Reddy VC,Patel SV,Hodge DO,et al.Corneal sensitivity,blink rate,and corneal nerve density in progressive supranuclear palsy and Parkinson disease[J].Cornea,2013,32(5):631-635.
[24]
Tamer C,Melek IM,Duman T,et al.Tear film tests in Parkinson′s disease patients[J].Ophthalmology,2005,112(10):1795.
[25]
Veerapaneni KD,Kapoor N,Veerapaneni P,et al.Trigeminal neuropathy[M].Treasure Island(FL):StatPearls,2024.
[26]
Zadro I,Barun B,Habek M,etal.Isolated cranial nerve palsies inmultiple sclerosis[J].Clin Neurol Neurosurg,2008,110(9):886-888.
[27]
Annunziata P,De-Santi L,Di-Rezze S,etal.Clinical featuresof Sjogren′s syndrome in patients with multiple sclerosis[J].Acta Neurol Scand,2011,124(2):109-114.
[28]
Oganov A,Yazdanpanah G,Jabbehdari S,etal.Dry eye disease and blinking behaviors:A narrative review of methodologies for measuring blink dynamics and inducing blink response[J].Ocul Surf,2023,29:166-174.
[29]
Rodriguez JD, Lane KJ, Ousler GW, et al. Blink:characteristics,controls,and relation to dry eyes[J].Curr Eye Res,2018,43(1):52-66.
[30]
Hamedani AG, Gold DR. Eyelid dysfunction in neurodegenerative,neurogenetic,and neurometabolic disease[J].Front Neurol,2017,8:329.
[31]
D′Antonio F,Bartolo MI,Ferrazzano G,et al.Blink rate study in patients with Alzheimer′s disease,mild cognitive impairment and subjective cognitive decline[J].Curr Alzheimer Res,2021,18(14):1104-1110.
[32]
Biggio M,Caligiore D,D′Antoni F,et al.Machine learning for exploring neurophysiological functionality in multiple sclerosis based on trigeminal and hand blink reflexes[J].Sci Rep,2022,12(1):21078.
[33]
Dežmalj-Grbelja L,Mikula I,ĈoriĉL,et al.The value of blink reflex in early diagnosis of multiple sclerosis[J].Acta Clin Croat,2021,60(1):10-15.
[34]
Avetisov SE,Surnina ZV.Confocal microscopy of the corneal nerve fibers[J].Vestn Oftalmol,2023,139(2):38-45.
[35]
Park JK,Charlson ES,Leyngold I,et al.Cornealtcomes[J].Ophthalmic Plast Reconstr Surg,2020,36(5):431-437.
[36]
Verma S,Kumar A,Tripathi T,et al.Muscarinic and nicotinic acetylcholine receptor agonists:current scenario in Alzheimer′s disease therapy[J].J Pharm Pharmacol,2018,70(8):985-993.
[37]
Adamec I,Krbot-Skoriĉ M, Habek M. Understanding and managing autonomic dysfunction in personswithmultiple sclerosis[J].Expert Rev Neurother,2021,21(12):1409-1417.
[38]
Gomes J,Azar DT,Baudouin C,et al.TFOS DEWS Ⅱiatrogenic report[J].Ocul Surf,2017,15(3):511-538.
[1] 王胜男, 孙挥宇, 接英, 谢雯, 毛菲菲, 李丹, 鲁丹, 刘夕瑶. 慢性丙型肝炎患者干眼临床特征[J/OL]. 中华实验和临床感染病杂志(电子版), 2023, 17(01): 48-54.
[2] 雷双银, 习剑鑫, 贺羽轩, 姚静宜, 石博雅, 马杰, 池光范, 李美英. 间充质干细胞源外泌体在神经退行性疾病治疗中的应用与进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2023, 13(02): 93-100.
[3] 汪毅仁, 江晓丹, 李佳曦, 赵天瑶, 李学民. 干眼的症状、体征与焦虑及抑郁相关性的临床研究[J/OL]. 中华眼科医学杂志(电子版), 2024, 14(04): 212-216.
[4] 刘涵, 张蓝月, 沈强. 眼表重建技术的研究进展[J/OL]. 中华眼科医学杂志(电子版), 2024, 14(03): 182-186.
[5] 张莉, 左晓玲, 王宁利. 神经退行性疾病脱髓鞘病变及扩散张量成像检测技术的研究进展[J/OL]. 中华眼科医学杂志(电子版), 2024, 14(01): 52-56.
[6] 张涛, 汪建茹, 赵瑾超, 葛程, 钱竹韵, 陶勇. 基质金属蛋白酶9即时检测对干眼诊断效能分析的临床研究[J/OL]. 中华眼科医学杂志(电子版), 2024, 14(01): 14-19.
[7] 李新星, 方晏红, 陈会振, 张蓝月, 刘涵. 维生素D与眼病关系的研究进展[J/OL]. 中华眼科医学杂志(电子版), 2023, 13(06): 366-370.
[8] 王宇珊, 郑晓汾, 于花, 韩玉萍, 宁晓玲. 翼状胬肉患者术中角膜、结膜缺损面积与其术后干眼相关性的临床研究[J/OL]. 中华眼科医学杂志(电子版), 2023, 13(06): 344-349.
[9] 王霜, 接英. 近视眼与干眼相关性的研究进展[J/OL]. 中华眼科医学杂志(电子版), 2023, 13(05): 311-315.
[10] 王文莹, 田磊, 潘志强. 3%地夸磷索钠滴眼液治疗干眼前后自觉症状改善和体征变化关系的临床研究[J/OL]. 中华眼科医学杂志(电子版), 2023, 13(05): 279-284.
[11] 白静怡, 黄轩, 张益权, 田颖, 陶勇. 小鼠干眼模型构建及其角膜特征检测的实验研究[J/OL]. 中华眼科医学杂志(电子版), 2023, 13(01): 12-17.
[12] 荆大兰, 江晓丹, 杨嘉瑞, 李学民. 眼表菌群改变与干眼关系的研究进展[J/OL]. 中华眼科医学杂志(电子版), 2022, 12(06): 372-376.
[13] 程英, 安文在, 林丹婷, 王宁利. 肠道菌群与眼部常见疾病关系的研究进展[J/OL]. 中华眼科医学杂志(电子版), 2022, 12(05): 305-309.
[14] 张卓媛, 杨二万, 田志成, 包明冬, 罗鹏. 慢性创伤性脑病的研究新进展[J/OL]. 中华神经创伤外科电子杂志, 2023, 09(06): 360-366.
[15] 周佳佳, 俞莹, 梁舒. 视频终端视相关性干眼症的机制研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(04): 402-406.
阅读次数
全文


摘要